PL3556752T3 - Związki n-((het)arylometylo-heteroarylo-karboksyamidowe jako inhibitory kalikreiny osoczowej - Google Patents

Związki n-((het)arylometylo-heteroarylo-karboksyamidowe jako inhibitory kalikreiny osoczowej

Info

Publication number
PL3556752T3
PL3556752T3 PL19176610T PL19176610T PL3556752T3 PL 3556752 T3 PL3556752 T3 PL 3556752T3 PL 19176610 T PL19176610 T PL 19176610T PL 19176610 T PL19176610 T PL 19176610T PL 3556752 T3 PL3556752 T3 PL 3556752T3
Authority
PL
Poland
Prior art keywords
arylomethyl
kalikrein
het
heteroaryl
inhibitors
Prior art date
Application number
PL19176610T
Other languages
English (en)
Inventor
Rebecca Louise DAVIE
Hannah Joy EDWARDS
David Michael Evans
Simon Teanby Hodgson
Original Assignee
Kalvista Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52349552&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3556752(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kalvista Pharmaceuticals Limited filed Critical Kalvista Pharmaceuticals Limited
Publication of PL3556752T3 publication Critical patent/PL3556752T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL19176610T 2014-11-27 2015-11-26 Związki n-((het)arylometylo-heteroarylo-karboksyamidowe jako inhibitory kalikreiny osoczowej PL3556752T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1421083.5A GB201421083D0 (en) 2014-11-27 2014-11-27 Enzyme inhibitors
EP15804210.1A EP3224256B1 (en) 2014-11-27 2015-11-26 N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors,
PCT/GB2015/053615 WO2016083820A1 (en) 2014-11-27 2015-11-26 N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors,
EP19176610.4A EP3556752B1 (en) 2014-11-27 2015-11-26 N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

Publications (1)

Publication Number Publication Date
PL3556752T3 true PL3556752T3 (pl) 2022-05-02

Family

ID=52349552

Family Applications (3)

Application Number Title Priority Date Filing Date
PL19182383T PL3567037T3 (pl) 2014-11-27 2015-11-26 Związki n-((het)arylometylo-heteroarylo-karboksyamidowe jako inhibitory kalikreiny osoczowej
PL15804210T PL3224256T3 (pl) 2014-11-27 2015-11-26 Związki n-((het)arylometylo-heteroarylo-karboksyamidowe jako inhibitory kalikreiny osoczowej
PL19176610T PL3556752T3 (pl) 2014-11-27 2015-11-26 Związki n-((het)arylometylo-heteroarylo-karboksyamidowe jako inhibitory kalikreiny osoczowej

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL19182383T PL3567037T3 (pl) 2014-11-27 2015-11-26 Związki n-((het)arylometylo-heteroarylo-karboksyamidowe jako inhibitory kalikreiny osoczowej
PL15804210T PL3224256T3 (pl) 2014-11-27 2015-11-26 Związki n-((het)arylometylo-heteroarylo-karboksyamidowe jako inhibitory kalikreiny osoczowej

Country Status (39)

Country Link
US (7) US10364238B2 (pl)
EP (4) EP3224256B1 (pl)
JP (5) JP6653702B2 (pl)
KR (2) KR102496404B1 (pl)
CN (2) CN107108576B (pl)
AR (2) AR102850A1 (pl)
AU (2) AU2015352193B2 (pl)
BR (1) BR112017010882B8 (pl)
CA (1) CA2967894C (pl)
CL (1) CL2017001362A1 (pl)
CO (1) CO2017006230A2 (pl)
CY (3) CY1122255T1 (pl)
DK (3) DK3224256T3 (pl)
EC (1) ECSP17039127A (pl)
ES (3) ES2745815T3 (pl)
FI (1) FIC20265004I1 (pl)
GB (1) GB201421083D0 (pl)
HR (3) HRP20220314T1 (pl)
HU (3) HUE047425T2 (pl)
IL (2) IL278182B (pl)
LT (3) LT3556752T (pl)
MA (3) MA52063B1 (pl)
MD (3) MD3224256T2 (pl)
ME (1) ME03514B (pl)
MX (2) MX2020013038A (pl)
MY (1) MY176853A (pl)
NZ (1) NZ731945A (pl)
PH (1) PH12017500901B1 (pl)
PL (3) PL3567037T3 (pl)
PT (3) PT3224256T (pl)
RS (3) RS63155B1 (pl)
RU (1) RU2707870C2 (pl)
SG (2) SG10201907819WA (pl)
SI (3) SI3556752T1 (pl)
SM (3) SMT202200107T1 (pl)
TW (2) TWI741377B (pl)
UA (1) UA123087C2 (pl)
WO (1) WO2016083820A1 (pl)
ZA (1) ZA201907052B (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
GB201421083D0 (en) * 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
EA202191548A1 (ru) 2015-10-01 2021-09-02 Байокрист Фармасьютикалз, Инк. Ингибиторы плазменного калликреина человека
GB201609519D0 (en) * 2016-05-31 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyr idin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide
RU2739447C2 (ru) * 2016-05-31 2020-12-24 Калвиста Фармасьютикалз Лимитед Производные пиразола в качестве ингибиторов калликреина
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) * 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
WO2018200674A1 (en) * 2017-04-26 2018-11-01 Mitobridge, Inc. Dynamin-1-like protein inhibitors
GB201721515D0 (en) * 2017-12-21 2018-02-07 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibtor
IL274557B2 (en) * 2017-11-29 2024-09-01 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibitor
TW201925188A (zh) * 2017-11-29 2019-07-01 英商卡爾維斯塔製藥有限公司 酶抑制劑
GB201719882D0 (en) * 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of a plasma kallikrein inhibitor and salts thereof
GB201719881D0 (en) * 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
WO2019178129A1 (en) 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
GB201910125D0 (en) * 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of angioedema
GB201910116D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
EP4031245A1 (en) 2019-09-18 2022-07-27 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
PL4031547T3 (pl) 2019-09-18 2024-10-07 Takeda Pharmaceutical Company Limited Inhibitory kalikreiny osoczowej i ich zastosowania
CN113004286B (zh) * 2019-12-20 2022-08-12 成都康弘药业集团股份有限公司 作为血浆激肽释放酶抑制剂的三环类化合物及其用途
TW202144331A (zh) * 2020-02-13 2021-12-01 德商百靈佳殷格翰國際股份有限公司 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物
CN115210230A (zh) * 2020-03-04 2022-10-18 南京明德新药研发有限公司 杂环类化合物
BR112022025528A2 (pt) 2020-06-16 2023-01-17 Merck Sharp & Dohme Llc Composto, composição farmacêutica, e, métodos para tratar atividade visual prejudicada, retinopatia diabética, edema macular diabético, oclusão de veia retinal, angioedema hereditário, diabete, pancreatite, hemorragia cerebral, nefropatia, cardiomiopatia, neuropatia, doença intestinal inflamatória, artrite, inflamação, choque séptico, hipotensão, câncer, síndrome da angústia respiratória do adulto, coagulação intravascular disseminada, coagulação sanguínea durante cirurgia de desvio cardiopulmonar ou hemorragia do pós-operatório de cirurgia e para tratar uveíte, uveíte posterior, edema macular relacionado com a idade úmido
TW202228686A (zh) 2020-10-15 2022-08-01 英商卡爾維斯塔製藥有限公司 血管性水腫之治療
WO2022084693A1 (en) 2020-10-23 2022-04-28 Kalvista Pharmaceuticals Limited Treatments of angioedema
US20240122909A1 (en) 2021-02-09 2024-04-18 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
WO2023002219A1 (en) 2021-07-23 2023-01-26 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
WO2023185634A1 (zh) * 2022-03-30 2023-10-05 南京明德新药研发有限公司 作为血浆激肽释放酶抑制剂的杂环类化合物
PL4288036T3 (pl) 2022-04-27 2024-11-25 Kalvista Pharmaceuticals Limited Preparaty inhibitora kalikreiny osoczowej
CA3262952A1 (en) * 2022-07-29 2024-02-01 Rezolute, Inc. PLASMA KALLICEREIN INHIBITORS
WO2024180100A1 (en) 2023-02-27 2024-09-06 Kalvista Pharmaceuticals Limited New solid form of a plasma kallikrein inhibitor
WO2025001956A1 (zh) 2023-06-30 2025-01-02 远森制药（杭州）有限公司 杂芳族甲酰胺类化合物及其在医药上的应用
WO2025153806A1 (en) 2024-01-15 2025-07-24 Kalvista Pharmaceuticals Limited Methods for determining amidolytic activity
WO2025172692A1 (en) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Oral sebetralstat for the treatment of an attack of hereditary angioedema
WO2025172693A1 (en) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Oral sebetralstat for the treatment of an attack of hereditary angioedema

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
SE9301911D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
US5786328A (en) 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US7101878B1 (en) 1998-08-20 2006-09-05 Agouron Pharmaceuticals, Inc. Non-peptide GNRH agents, methods and intermediates for their preparation
KR100722344B1 (ko) 1999-04-15 2007-05-29 브리스톨-마이어스스퀴브컴파니 환형 단백질 티로신 키나제 억제제
ATE355064T1 (de) 2001-10-26 2006-03-15 Angeletti P Ist Richerche Bio Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
AU2002363250A1 (en) 2001-11-01 2003-05-12 Icagen, Inc. Pyrazole-amides and-sulfonamides
GB0205527D0 (en) 2002-03-08 2002-04-24 Ferring Bv Inhibitors
PL212090B1 (pl) 2002-04-26 2012-08-31 Lilly Co Eli Pochodna triazolu
EP1426364A1 (en) 2002-12-04 2004-06-09 Aventis Pharma Deutschland GmbH Imidazole-derivatives as factor Xa inhibitors
DE10301300B4 (de) 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
ATE551324T1 (de) 2003-02-03 2012-04-15 Janssen Pharmaceutica Nv Chinolin-amid-derivate als modulatoren von vanilloid-vr1-rezeptoren
CN1934255B (zh) 2003-08-27 2012-07-11 奥普索特克公司 用于治疗眼新血管疾病的组合治疗
TW200526588A (en) * 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
GB0403155D0 (en) 2004-02-12 2004-03-17 Vernalis Res Ltd Chemical compounds
EP1568698A1 (en) 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrole-derivatives as factor Xa inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
WO2006025714A1 (en) 2004-09-03 2006-03-09 Yuhan Corporation PYRROLO[3,2-c]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF
US8841259B2 (en) 2005-02-24 2014-09-23 Joslin Diabetes Center Compositions and methods for treating vascular permeability
GB0508472D0 (en) 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
KR101142363B1 (ko) 2005-06-27 2012-05-21 주식회사유한양행 피롤로피리딘 유도체를 포함하는 항암제 조성물
WO2007011328A1 (en) 2005-07-14 2007-01-25 Jackson Kenneth A A method for disabling a hypodermic needle after use
WO2007011626A2 (en) 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20070254894A1 (en) 2006-01-10 2007-11-01 Kane John L Jr Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation
GB0606876D0 (en) * 2006-04-05 2006-05-17 Glaxo Group Ltd Compounds
US20070258976A1 (en) 2006-05-04 2007-11-08 Ward Keith W Combination Therapy for Diseases Involving Angiogenesis
AU2007271182B2 (en) 2006-07-06 2012-03-15 Glaxo Group Limited Substituted N-phenylmethyl -5-oxo-proline-2-amides as P2X7-receptor antagonists and their methods of use
CA2658523C (en) 2006-07-31 2012-06-12 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
AU2007341232B2 (en) 2006-12-29 2013-01-31 AbbVie Deutschland GmbH & Co. KG Carboxamide compounds and their use as calpain inhibitors
US20100119512A1 (en) 2007-01-25 2010-05-13 Joslin Diabetes Center Methods of diagnosing, treating, and preventing increased vascular permeability
EP2139887A2 (en) 2007-03-07 2010-01-06 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
WO2008121670A1 (en) 2007-03-30 2008-10-09 Sanofi-Aventis Pyrimidine hydrazide compounds as pgds inhibitors
KR20090127435A (ko) 2007-04-03 2009-12-11 글락소 그룹 리미티드 Ｐ2ｘ7 조절제로서의 이미다졸리딘 카르복스아미드 유도체
JP5390520B2 (ja) 2007-07-26 2014-01-15 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト 新規殺菌剤
WO2009026407A1 (en) 2007-08-22 2009-02-26 Allergan, Inc. Pyrrole compounds having sphingosine-1-phosphate receptor agonist or antagonist biological activity
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009083553A1 (en) 2007-12-31 2009-07-09 Rheoscience A/S Azine compounds as glucokinase activators
US8658685B2 (en) 2008-01-31 2014-02-25 Activesite Pharmaceuticals, Inc. Methods for treatment of kallikrein-related disorders
WO2009106980A2 (en) 2008-02-29 2009-09-03 Pfizer Inc. Indazole derivatives
EP2265601B1 (en) 2008-03-13 2012-02-01 Bristol-Myers Squibb Company Pyridazine derivatives as factor xia inhibitors
AU2009269178B2 (en) 2008-07-08 2012-09-06 Daiichi Sankyo Company, Limited Nitrogen-containing aromatic heterocyclyl compound
US8324385B2 (en) 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
CA2783801A1 (en) 2009-12-18 2011-06-23 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
JP2011157349A (ja) 2010-01-07 2011-08-18 Daiichi Sankyo Co Ltd 含窒素芳香族ヘテロシクリル化合物を含有する医薬組成物
BR112012019042A8 (pt) 2010-01-28 2017-12-26 The Medicines Company Leipzig Gmbh compostos inibidores de serina protease tipo tripsina, seu uso, e seus processos de preparação
JP2013121919A (ja) 2010-03-25 2013-06-20 Astellas Pharma Inc 血漿カリクレイン阻害剤
WO2012004678A2 (en) 2010-07-07 2012-01-12 The Medicines Company (Leipzig) Gmbh Serine protease inhibitors
WO2012009009A2 (en) 2010-07-14 2012-01-19 Addex Pharma S.A. Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
US9290485B2 (en) * 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
EP2458315B1 (de) 2010-11-25 2017-01-04 Balcke-Dürr GmbH Regenerativer Wärmetauscher mit zwangsgeführter Rotordichtung
EP2697196A1 (en) 2011-04-13 2014-02-19 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
WO2012174362A1 (en) 2011-06-17 2012-12-20 Research Triangle Institute Pyrazole derivatives as cannabinoid receptor 1 antagonists
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
EP2760829B1 (en) 2011-09-27 2016-05-18 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
US9249096B2 (en) 2011-09-27 2016-02-02 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
EP2807156A1 (en) 2012-01-27 2014-12-03 Novartis AG Aminopyridine derivatives as plasma kallikrein inhibitors
US20140378474A1 (en) * 2012-01-27 2014-12-25 Novartis Ag 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
JP5989805B2 (ja) 2012-02-10 2016-09-07 コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． メチル基変更酵素の調節物質、組成物及びその使用
WO2013130603A1 (en) 2012-02-27 2013-09-06 Board Of Regents, The University Of Texas System Ganglioside gd2 as a marker and target on cancer stem cells
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
PE20151722A1 (es) 2013-01-08 2015-11-19 European Molecular Biology Lab Embl Derivados de pirimidona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral
GB201300304D0 (en) * 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
AU2014207420B2 (en) 2013-01-20 2018-08-09 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
CN110101699A (zh) 2013-03-15 2019-08-09 维颂公司 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物
RU2712621C2 (ru) * 2013-05-23 2020-01-30 Калвиста Фармасьютикалз Лимитед Азотсодержащие гетероциклические производные, полезные в качестве ингибитора калликреина плазмы
GB2517908A (en) 2013-08-14 2015-03-11 Kalvista Pharmaceuticals Ltd Bicyclic inhibitors
MX366498B (es) 2013-08-14 2019-07-11 Kalvista Pharmaceuticals Ltd Inhibidores de calicreina plasmatica.
KR20160106627A (ko) 2013-12-30 2016-09-12 라이프에스씨아이 파마슈티컬스, 인크. 치료적 억제 화합물
US9611252B2 (en) 2013-12-30 2017-04-04 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
HUE052668T2 (hu) 2014-03-07 2021-05-28 Biocryst Pharm Inc Trifluorometillel szubsztituált pirazolok mint humán plazma kallikrein-gátlók
WO2015171526A2 (en) 2014-05-05 2015-11-12 Global Blood Therapeutics, Inc. Tricyclic pyrazolopyridine compounds
US9695166B2 (en) 2014-05-05 2017-07-04 Global Blood Therapeutics, Inc. Pyrazolopyridine pyrazolopyrimidine and related compounds
EP3169325B1 (en) 2014-07-16 2021-04-28 Attune Pharmaceuticals, Inc. Therapeutic inhibitory compounds
US10905683B2 (en) 2014-08-22 2021-02-02 Biocryst Pharmaceuticals, Inc. Compositions and uses of amidine derivatives
CN106687445A (zh) 2014-09-17 2017-05-17 维颂公司 作为丝氨酸蛋白酶抑制剂的吡唑基取代的吡啶酮化合物
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421088D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
KR102824411B1 (ko) 2015-02-27 2025-06-23 베르선 코포레이션 세린 프로테아제 저해제로서의 치환된 피라졸 화합물
CA2991174A1 (en) 2015-07-01 2017-01-05 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
CA2991171A1 (en) 2015-07-01 2017-01-05 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
JP6917988B2 (ja) 2015-10-27 2021-08-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 血漿カリクレイン阻害薬としてのヘテロアリールカルボキサミド誘導体
US10640486B2 (en) 2015-10-27 2020-05-05 Boehringer Ingelheim International Gmbh Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
GB201609519D0 (en) 2016-05-31 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyr idin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide
RU2739447C2 (ru) 2016-05-31 2020-12-24 Калвиста Фармасьютикалз Лимитед Производные пиразола в качестве ингибиторов калликреина
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609602D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
WO2018011628A1 (en) 2016-07-11 2018-01-18 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
TW201925188A (zh) 2017-11-29 2019-07-01 英商卡爾維斯塔製藥有限公司 酶抑制劑
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
GB201719882D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of a plasma kallikrein inhibitor and salts thereof

Also Published As

Publication number Publication date
EP3224256A1 (en) 2017-10-04
IL278182A (en) 2020-11-30
US11198691B2 (en) 2021-12-14
US20190330200A1 (en) 2019-10-31
HRP20210350T1 (hr) 2021-04-16
SMT202100112T1 (it) 2021-05-07
EP3556752A1 (en) 2019-10-23
AU2019240616B2 (en) 2021-07-29
SI3556752T1 (sl) 2022-05-31
IL252287A0 (en) 2017-07-31
EP3224256B1 (en) 2019-07-03
MX2020013038A (es) 2022-12-09
MD3556752T2 (ro) 2022-07-31
GB201421083D0 (en) 2015-01-14
EP3567037A1 (en) 2019-11-13
NZ770256A (en) 2021-11-26
MX2017006823A (es) 2017-09-27
CL2017001362A1 (es) 2018-02-09
KR102496404B1 (ko) 2023-02-06
WO2016083820A1 (en) 2016-06-02
TW201625548A (zh) 2016-07-16
RU2017122364A3 (pl) 2019-06-19
HUE057647T2 (hu) 2022-05-28
JP7148683B2 (ja) 2022-10-05
CY1122255T1 (el) 2020-11-25
FIC20265004I1 (fi) 2026-01-13
CN110577519A (zh) 2019-12-17
JP2025000918A (ja) 2025-01-07
MA47217B1 (fr) 2021-04-30
US11001578B2 (en) 2021-05-11
MA41014A (fr) 2017-10-04
HUE047425T2 (hu) 2020-04-28
ECSP17039127A (es) 2017-12-01
PT3224256T (pt) 2019-09-23
JP2022180520A (ja) 2022-12-06
LT3567037T (lt) 2021-02-25
PT3567037T (pt) 2021-02-23
JP6653702B2 (ja) 2020-02-26
LT3224256T (lt) 2019-09-25
KR102267623B1 (ko) 2021-06-18
SMT201900497T1 (it) 2019-11-13
IL278182B (en) 2022-09-01
IL252287B (en) 2020-11-30
BR112017010882B1 (pt) 2023-10-31
CY1125214T1 (el) 2023-06-09
US20180319782A1 (en) 2018-11-08
HRP20220314T1 (hr) 2022-05-13
US20200199116A1 (en) 2020-06-25
UA123087C2 (uk) 2021-02-17
RU2017122364A (ru) 2018-12-27
KR20170090451A (ko) 2017-08-07
MA41014B1 (fr) 2019-09-30
TW202026285A (zh) 2020-07-16
JP2021185138A (ja) 2021-12-09
AR102850A1 (es) 2017-03-29
AU2015352193A1 (en) 2017-06-08
US20220289729A1 (en) 2022-09-15
ES2908303T3 (es) 2022-04-28
CA2967894C (en) 2024-01-30
US11084809B2 (en) 2021-08-10
AU2019240616A1 (en) 2019-10-17
CY1124046T1 (el) 2022-05-27
PH12017500901B1 (en) 2022-04-27
HK1244268A1 (en) 2018-08-03
US20190300517A1 (en) 2019-10-03
RU2707870C2 (ru) 2019-12-02
CA2967894A1 (en) 2016-06-02
JP2020033357A (ja) 2020-03-05
SG11201703988PA (en) 2017-06-29
EP3556752B1 (en) 2022-01-05
SI3224256T1 (sl) 2019-12-31
TWI686383B (zh) 2020-03-01
RS61497B1 (sr) 2021-03-31
MA52063A (fr) 2021-05-26
BR112017010882A2 (pt) 2017-12-26
DK3224256T3 (da) 2019-09-23
CN107108576A (zh) 2017-08-29
DK3556752T3 (da) 2022-03-07
ES2858082T3 (es) 2021-09-29
AU2015352193B2 (en) 2019-10-10
NZ731945A (en) 2021-07-30
MD3224256T2 (ro) 2019-12-31
US20200361923A1 (en) 2020-11-19
MY176853A (en) 2020-08-24
DK3567037T3 (da) 2021-02-08
MA47217A (fr) 2019-11-13
BR112017010882B8 (pt) 2023-11-14
SG10201907819WA (en) 2019-09-27
PH12017500901A1 (en) 2017-12-18
MX378283B (es) 2025-03-10
LT3556752T (lt) 2022-03-10
HUE053317T2 (hu) 2021-06-28
PL3567037T3 (pl) 2021-06-14
ME03514B (me) 2020-04-20
KR20210075227A (ko) 2021-06-22
PT3556752T (pt) 2022-04-14
US10364238B2 (en) 2019-07-30
ES2745815T3 (es) 2020-03-03
AR121273A2 (es) 2022-05-04
RS59395B1 (sr) 2019-11-29
RS63155B1 (sr) 2022-05-31
CO2017006230A2 (es) 2017-09-11
US20250074903A1 (en) 2025-03-06
US10611758B2 (en) 2020-04-07
SI3567037T1 (sl) 2021-04-30
SMT202200107T1 (it) 2022-05-12
CN107108576B (zh) 2020-03-10
EP3567037B1 (en) 2020-12-23
MD3567037T2 (ro) 2021-05-31
HRP20191524T1 (hr) 2019-11-29
JP2017535568A (ja) 2017-11-30
ZA201907052B (en) 2025-01-29
EP4039681A1 (en) 2022-08-10
MA52063B1 (fr) 2022-01-31
PL3224256T3 (pl) 2020-01-31
TWI741377B (zh) 2021-10-01
JP6995101B2 (ja) 2022-01-14
RU2019131174A (ru) 2019-10-10

Similar Documents

Publication Publication Date Title
IL278182A (en) N-((het)arylmethyl)-heteroaryl-carboxamide compounds as plasma kallikrein inhibitors
IL263586A (en) Inhibitors of the menin-mll interaction
PL3209656T3 (pl) Związki indolo-karboksyamidu użyteczne jako inhibitory kinazy
IL257880B (en) Beta-lactamase inhibitors
DK3442980T3 (da) Heterocykliske forbindelser som ret-kinase-hæmmere
DK3371190T3 (da) Heterocykliske forbindelser som pi3k-gamma-inhibitorer
PL3105226T3 (pl) Cyklopropyloaminy jako inhibitory LSD1
LT3303334T (lt) Tirozinkinazės inhibitoriai
ME03610B (me) Naftiridinska jedinjenja kao inhibitori jak kinaze
HUE042335T2 (hu) ROR-gamma dihidropirrolopiridin inhibitorai
IL248661B (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors
DK3466432T3 (da) Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner
SI3224255T1 (sl) Spojine N-((HET)ARILMETIL)-HETEROARIL-KARBOKSAMIDOV kot zaviralci plazemskega kalikreina
DK3116475T3 (da) Dopa-decarboxylasehæmmersammensætninger
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
TH1501006052A (th) สารยับยั้ง bacei